Opentrons logo

Press Release: Opentrons Announces $200 Million Series C Round Led by SoftBank

Opentrons will use this funding to scale its automated lab platform for life sciences and healthcare.

NEW YORK, NY – SEPTEMBER 23TH, 2021: Today Opentrons Labworks Inc. has announced SoftBank Vision Fund 2* has led the company’s $200 million Series C investment with participation by Khosla Ventures. Opentrons will use this fundraising round to further invest in its automated lab platform globally.

“Biology opens the door to solve many of humanity’s grand challenges. For far too long, scientists and clinicians have been locked-in by slow, expensive, and overly complex lab solutions that underpin their work,” said Jon Brennan-Badal, CEO of Opentrons. “Opentrons’ platform provides the key to unlock their potential. We are enabling more R&D, more testing, more biology to unleash innovation in life sciences and healthcare.”

The lab platform uniquely integrates the development of lab robotics, assays, and operations to create high-quality and cost-effective end solutions. Opentrons uses this platform to provide the following industry-specific lab solutions:

“Opentrons is building a disruptive automated lab platform that is aiming to transform healthcare and life sciences with a vertically integrated, low-cost solution,” said Angela Du, Investment Director at SoftBank Investment Advisers. “The company has an extremely high value proposition in the lab diagnostics and synthetic genomics markets where its robotics and consumables serve as foundational components today. We look forward to partnering with CEO Jonathan Brennan-Badal to help the company accelerate growth and commercialize new offerings.”

The Series C round will enable significant investment in the Opentrons platform. In particular, the investment will support development of new robotic tools, an expanded biofoundry, new diagnostic tests, and additional diagnostic labs. All of these initiatives will drive better, more affordable solutions for our life science and healthcare customers.